Sanofi-aventis Canada announced in June, 2018 that it will immediately stop the distribution of Amaryl (Glimipiride) 1,2 and 4mg tabs in Canada.

Glimepiride (original trade name Amaryl) is an orally available medium-to-long-acting Sulfonylurea antidiabetic drug.